Imaging Scan Tests Advanced Prostate Cancer That Is Hard to Detect
Tests a PET scan with fluciclovine in adults with advanced prostate cancer.
Plain-language title generated from the registry record
Registry title: Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
Key facts
- Where
- Boston, United StatesSee the 2 sites
- Phase
- Phase 1
Where in United States
- Brigham and Womens HospitalBoston, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Brigham and Women's Hospital
- Trial code
- NCT06062745
- Record updated
- 29 October 2026
- Original description
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features.Read full original descriptionShow less
A Pilot Study for Detection of PSMA-Low Castration Resistant and Neuroendocrine Prostate Cancer With 18F-fluciclovine PET/CT Imaging
This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of advanced prostate cancer that either has low prostate-specific membrane antigen (PSMA) expression or has neuroendocrine features.
The name of the study interventions are:
* 18F-fluciclovine-PET/CT scan * Two research blood collections
Inclusion: Participants must have histologically confirmed prostate cancer that is metastatic and one of the following: CRPC with PSMA-low disease defined by whole-body SUVmean ≤ 10 determined by standard-of-care 68Ga-PSMA-11 PET/CT imaging with at least 5 metastatic lesions OR NEPC pathology based on tumor biopsy. This may include morphology consistent with small cell carcinoma or mixed adenocarcinoma/NE features and/or IHC staining for NE markers. Participants should have at least 5 metastatic lesions; Must have either already had standard of care 68Ga-PSMA PET/CT scan or be planned for 68Ga-PSMA PET/CT scan before or after the planned 18F-fluciclovine-PET/CT; Age ≥18 years. Since no dosing or adverse event data are currently available on the use of 18F-fluciclovine in participants <18 years of age, and most prostate cancer occurs in the adult population, children are excluded from this study but will be eligible for future pediatric trials; ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A); Ability and willingness to comply with the study procedures; The effects of 18F-fluciclovine on the developing human fetus are unknown. For this reason and because radiopharmaceuticals may be teratogenic, men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for 24 hours after the PET/CT scan is completed; Ability to understand and the willingness to sign a written informed consent document.
Exclusion: Participants with other known malignancy requiring treatment; History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-fluciclovine; Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements; Any past or current condition that in the opinion of the study investigators would confound the results of the study or pose additional risk to the patient by their participation in the study; Contraindications for PET/CT including:; Severe claustrophobia.